The effect of vitamin D3 supplementation on markers of cardiovascular health in hyperparathyroid, vitamin D insufficient women: a randomized placebo-controlled trial.

Plain-language guide to PMID 30043092 (2018): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 81 women, hyperparathyroidism.

Key Facts

PMID: 30043092
Journal: Endocrine
Year: 2018
Study type: Randomized Controlled Trial
Authors: Bislev LS et al. (9 authors)
DOI: 10.1007/s12020-018-1659-4

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism in this randomized controlled trial publication.

Emerging data supports an association between parathyroid hormone (PTH) and aldosterone.

Who Took Part

According to the abstract, 81 women were involved.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the women and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Markers of cardiovascular health were defined as changes in the plasma RAAS, glycated hemoglobin, lipids, and lipoproteins, blood pressure, vascular stiffness, heart rate, and cardiac conductivity.

What Was Measured

Topics PubMed links to this paper include Blood Pressure, Cardiovascular System, Cholecalciferol, Heart Rate, Hormone Replacement Therapy, Hyperparathyroidism and Vascular Stiffness.

The authors tagged it with the keywords Aldosterone, Cholesterol, Parathyroid hormone, Renin-angiotensin-aldosterone system and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 81 women in people with hyperparathyroidism.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Endocrine), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.